<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Psychopharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">JOP</journal-id>
      <journal-id journal-id-type="hwp">spjop</journal-id>
      <journal-title-group>
        <journal-title>Journal of Psychopharmacology (Oxford, England)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0269-8811</issn>
      <issn pub-type="epub">1461-7285</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage UK: London, England</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34189985</article-id>
      <article-id pub-id-type="pmc">8801642</article-id>
      <article-id pub-id-type="doi">10.1177/02698811211026454</article-id>
      <article-id pub-id-type="publisher-id">10.1177_02698811211026454</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Papers</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6360-5224</contrib-id>
          <name>
            <surname>McCulloch</surname>
            <given-names>Drummond E-Wen</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Madsen</surname>
            <given-names>Martin Korsbak</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
          <xref rid="aff2-02698811211026454" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5439-4637</contrib-id>
          <name>
            <surname>Stenbæk</surname>
            <given-names>Dea Siggaard</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
          <xref rid="aff3-02698811211026454" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kristiansen</surname>
            <given-names>Sara</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ozenne</surname>
            <given-names>Brice</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
          <xref rid="aff4-02698811211026454" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jensen</surname>
            <given-names>Peter Steen</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Knudsen</surname>
            <given-names>Gitte Moos</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
          <xref rid="aff2-02698811211026454" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8115-0611</contrib-id>
          <name>
            <surname>Fisher</surname>
            <given-names>Patrick MacDonald</given-names>
          </name>
          <xref rid="aff1-02698811211026454" ref-type="aff">1</xref>
          <xref rid="corresp1-02698811211026454" ref-type="corresp"/>
        </contrib>
      </contrib-group>
      <aff id="aff1-02698811211026454"><label>1</label>Neurobiology Research Unit and NeuroPharm, Rigshospitalet, Copenhagen, Denmark</aff>
      <aff id="aff2-02698811211026454"><label>2</label>Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark</aff>
      <aff id="aff3-02698811211026454"><label>3</label>Department of Psychology, University of Copenhagen, Copenhagen, Denmark</aff>
      <aff id="aff4-02698811211026454"><label>4</label>Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark</aff>
      <author-notes>
        <corresp id="corresp1-02698811211026454">Patrick MacDonald Fisher, Neurobiology Research Unit, Rigshospitalet Building 8057, 8 Inge Lehmanns Vej, Copenhagen 2100, Denmark. Email: <email>patrick@nru.dk</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>6</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2022</year>
      </pub-date>
      <volume>36</volume>
      <issue>1</issue>
      <fpage>74</fpage>
      <lpage>84</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2021</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
          <license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <sec id="section1-02698811211026454">
          <title>Background:</title>
          <p>Psilocybin is a psychedelic drug that has shown lasting positive effects on clinical symptoms and self-reported well-being following a single dose. There has been little research into the long-term effects of psilocybin on brain connectivity in humans.</p>
        </sec>
        <sec id="section2-02698811211026454">
          <title>Aim:</title>
          <p>Evaluate changes in resting-state functional connectivity (RSFC) at 1 week and 3 months after one psilocybin dose in 10 healthy psychedelic-naïve volunteers and explore associations between change in RSFC and related measures.</p>
        </sec>
        <sec id="section3-02698811211026454">
          <title>Methods:</title>
          <p>Participants received 0.2–0.3 mg/kg psilocybin in a controlled setting. Participants completed resting-state functional magnetic resonance imaging (fMRI) scans at baseline, 1-week and 3-month post-administration and [11C]Cimbi-36 PET scans at baseline and 1 week. We examined changes in within-network, between-network and region-to-region RSFC. We explored associations between changes in RSFC and psilocybin-induced phenomenology as well as changes in psychological measures and neocortex serotonin 2A receptor binding.</p>
        </sec>
        <sec id="section4-02698811211026454">
          <title>Results:</title>
          <p>Psilocybin was well tolerated and produced positive changes in well-being. At 1 week only, executive control network (ECN) RSFC was significantly decreased (Cohen’s <italic toggle="yes">d</italic> = −1.73, pFWE = 0.010). We observed no other significant changes in RSFC at 1 week or 3 months, nor changes in region-to-region RSFC. Exploratory analyses indicated that decreased ECN RSFC at 1 week predicted increased mindfulness at 3 months (<italic toggle="yes">r</italic> = −0.65).</p>
        </sec>
        <sec id="section5-02698811211026454">
          <title>Conclusions:</title>
          <p>These findings in a small cohort indicate that psilocybin affects ECN function within the psychedelic ‘afterglow’ period. Our findings implicate ECN modulation as mediating psilocybin-induced, long-lasting increases in mindfulness. Although our findings implicate a neural pathway mediating lasting psilocybin effects, it is notable that changes in neuroimaging measures at 3 months, when personality changes are observed, remain to be identified.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Functional magnetic resonance imaging</kwd>
        <kwd>resting-state connectivity</kwd>
        <kwd>psilocybin</kwd>
        <kwd>psychedelic</kwd>
        <kwd>executive control network</kwd>
      </kwd-group>
      <funding-group specific-use="FundRef">
        <award-group id="award1-02698811211026454">
          <funding-source id="funding1-02698811211026454">
<institution-wrap><institution>Innovationsfonden</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100012774</institution-id></institution-wrap>
</funding-source>
          <award-id rid="funding1-02698811211026454">4108–00004B</award-id>
        </award-group>
        <award-group id="award2-02698811211026454">
          <funding-source id="funding2-02698811211026454">
<institution-wrap><institution>Det Frie Forskningsråd</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004836</institution-id></institution-wrap>
</funding-source>
          <award-id rid="funding2-02698811211026454">6110-00518B</award-id>
        </award-group>
        <award-group id="award3-02698811211026454">
          <funding-source id="funding3-02698811211026454">
<institution-wrap><institution>Rigshospitalet</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100005111</institution-id></institution-wrap>
</funding-source>
          <award-id rid="funding3-02698811211026454">R130-A5324</award-id>
        </award-group>
        <award-group id="award4-02698811211026454">
          <funding-source id="funding4-02698811211026454">
<institution-wrap><institution>Lundbeckfonden</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003554</institution-id></institution-wrap>
</funding-source>
          <award-id rid="funding4-02698811211026454">R231-2016-3236</award-id>
        </award-group>
        <award-group id="award5-02698811211026454">
          <funding-source id="funding5-02698811211026454">
<institution-wrap><institution>H2020 Marie Skłodowska-Curie Actions</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100010665</institution-id></institution-wrap>
</funding-source>
          <award-id rid="funding5-02698811211026454">746850</award-id>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>typesetter</meta-name>
          <meta-value>ts1</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="section6-02698811211026454">
      <title>Introduction</title>
      <p>Psilocybin is a prodrug of the psychedelic psilocin (4-hydroxy-N,N-dimethyltryptamine) (<xref rid="bibr50-02698811211026454" ref-type="bibr">Nichols, 2016</xref>). Effects include profound alterations in consciousness that last approximately 6 h and are characterised by perceptual alterations and synaesthesia, experiences of non-duality and transcendence and profound changes in affect (<xref rid="bibr58-02698811211026454" ref-type="bibr">Preller and Vollenweider, 2018</xref>). Therapeutic effects of psilocybin have been reported following between one and three moderate-to-high doses (0.025–0.42 mg/kg) in brain-related disorders including major depressive disorder (MDD) (<xref rid="bibr15-02698811211026454" ref-type="bibr">Davis et al., 2020</xref>), treatment-resistant depression (<xref rid="bibr9-02698811211026454" ref-type="bibr">Carhart-Harris et al., 2018</xref>), obsessive-compulsive disorder (<xref rid="bibr47-02698811211026454" ref-type="bibr">Moreno et al., 2006</xref>), terminal cancer-associated anxiety (<xref rid="bibr26-02698811211026454" ref-type="bibr">Griffiths et al., 2016</xref>), demoralisation (<xref rid="bibr1-02698811211026454" ref-type="bibr">Anderson et al., 2020</xref>), as well as smoking (<xref rid="bibr36-02698811211026454" ref-type="bibr">Johnson et al., 2017</xref>) and alcohol addiction (<xref rid="bibr23-02698811211026454" ref-type="bibr">Garcia-Romeu et al., 2019</xref>). Psilocybin is currently in phase 2b for the treatment of treatment-resistant depression (COMPASS Pathways Ltd., London, UK) and in phase 2a for major depressive disorder (Usona Institute, Madison, WI, USA).</p>
      <p>Persistent changes in personality and mood have also been observed in healthy volunteers following a single medium-to-high dose of psilocybin. These include, for example, increases in personality traits openness and extraversion, decreases in neuroticism and increases in mindful awareness (<xref rid="bibr17-02698811211026454" ref-type="bibr">Erritzoe et al., 2018</xref>; <xref rid="bibr42-02698811211026454" ref-type="bibr">MacLean et al., 2011</xref>; <xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>). These therapeutic and personality effects appear to persist for at least months, and in some cases have been reported to last more than a year (<xref rid="bibr24-02698811211026454" ref-type="bibr">Gasser et al., 2014</xref>; <xref rid="bibr36-02698811211026454" ref-type="bibr">Johnson et al., 2017</xref>; <xref rid="bibr42-02698811211026454" ref-type="bibr">MacLean et al., 2011</xref>).</p>
      <p>The medicalisation of psychedelic drugs is expanding rapidly despite a limited understanding of the neurobiology underpinning therapeutic effects. Psychological theories of psychedelic therapy, such as reduced negative affect (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>), increased mindfulness (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>; <xref rid="bibr49-02698811211026454" ref-type="bibr">Murphy-Beiner and Soar, 2020</xref>; <xref rid="bibr72-02698811211026454" ref-type="bibr">Smigielski et al., 2019</xref>), increased cognitive flexibility (<xref rid="bibr49-02698811211026454" ref-type="bibr">Murphy-Beiner and Soar, 2020</xref>) and reduced experiential avoidance (<xref rid="bibr85-02698811211026454" ref-type="bibr">Zeifman et al., 2020</xref>) have been proposed, as well as increased acceptance and processing of traumatic autobiographical memories (<xref rid="bibr71-02698811211026454" ref-type="bibr">Sloshower et al., 2020</xref>), but these have no current grounding in neurobiology. Thus, in order to maximise psilocybin’s safety and efficacy as a potential therapeutic, it is important to investigate mechanisms by which psilocybin exerts its effects.</p>
      <p>Functional magnetic resonance imaging (fMRI) resting-state functional connectivity (RSFC) measures correlations between blood-oxygen-level-dependent (BOLD) signals in participants instructed to simply let their mind wander (<xref rid="bibr40-02698811211026454" ref-type="bibr">Lee et al., 2013</xref>). Despite not being focused on any task, the brain remains organised into networks (<xref rid="bibr62-02698811211026454" ref-type="bibr">Raichle, 2015</xref>), the character of which correlates with personality traits (<xref rid="bibr7-02698811211026454" ref-type="bibr">Cai et al., 2020</xref>; <xref rid="bibr33-02698811211026454" ref-type="bibr">Hsu et al., 2018</xref>) and aligns with known functional and structural topology (<xref rid="bibr76-02698811211026454" ref-type="bibr">Straathof et al., 2019</xref>). During the psychedelic experience, psilocybin produces a reduction in the synchronised BOLD activity of the major hubs of the default mode network (DMN) (<xref rid="bibr10-02698811211026454" ref-type="bibr">Carhart-Harris et al., 2012</xref>; <xref rid="bibr46-02698811211026454" ref-type="bibr">Mason et al., 2020</xref>), increases between-network RSFC (<xref rid="bibr63-02698811211026454" ref-type="bibr">Roseman et al., 2014</xref>) and increases global RSFC across the sensory cortex while decreasing the global connectivity in associative regions (<xref rid="bibr59-02698811211026454" ref-type="bibr">Preller et al., 2020</xref>). Similarly, lysergic acid diethylamide (LSD) increases RSFC between high-level association cortices, which correlates with subjective reports of ego-dissolution (<xref rid="bibr80-02698811211026454" ref-type="bibr">Tagliazucchi et al., 2016</xref>). Although understanding the neurological basis of the acute psychedelic experience is widely informative, the long-term psychological effects of psychedelics may be distinct (<xref rid="bibr11-02698811211026454" ref-type="bibr">Carhart-Harris et al., 2016</xref>).</p>
      <p>Five studies to date have reported effects on human brain function after the psychoactive effects of a classical psychedelic have subsided: two studies with ayahuasca and three with psilocybin (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>; <xref rid="bibr12-02698811211026454" ref-type="bibr">Carhart-Harris et al., 2017</xref>; <xref rid="bibr56-02698811211026454" ref-type="bibr">Pasquini et al., 2020</xref>; <xref rid="bibr64-02698811211026454" ref-type="bibr">Sampedro et al., 2017</xref>; <xref rid="bibr72-02698811211026454" ref-type="bibr">Smigielski et al., 2019</xref>). Post-drug brain imaging was performed within 24 h after the psychedelic session in all but one study (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>), during which time ‘afterglow’ effects and potential residual drug availability confounds relating effects to lasting changes (<xref rid="bibr43-02698811211026454" ref-type="bibr">Madsen et al., 2019</xref>; <xref rid="bibr45-02698811211026454" ref-type="bibr">Majić et al., 2015</xref>). By ‘afterglow’, we allude to the experience of ‘elevated and energetic mood with a relative freedom from concerns of the past and from guilt and anxiety’ up to 2 weeks after the experience, as described as early as during the 1960s and the ‘first-wave’ of psychedelic research (<xref rid="bibr29-02698811211026454" ref-type="bibr">Grob et al., 1996</xref>; <xref rid="bibr55-02698811211026454" ref-type="bibr">Pahnke, 1969</xref>). More recently, transient elevations in mood have been reported (<xref rid="bibr45-02698811211026454" ref-type="bibr">Majić et al., 2015</xref>; <xref rid="bibr49-02698811211026454" ref-type="bibr">Murphy-Beiner and Soar, 2020</xref>). <xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al. (2020)</xref> reported an increase in the number of significant RSFC across the brain in 12 healthy individuals from baseline to 1-week and 1-month post-psilocybin, hypothesising that psilocybin may increase emotional and brain plasticity. None of these previous studies evaluated correlations between change in RSFC and change in personality or other psychological traits. Furthermore, none of these studies have explored neuromolecular mechanisms mediating these effects. The psychoactive effects of psilocybin stem from agonism at the serotonin 2A receptor (5-HT2AR) (<xref rid="bibr81-02698811211026454" ref-type="bibr">Vollenweider et al., 1998</xref>). Positron emission tomography (PET) with the radiotracer [<sup>11</sup>C]Cimbi-36 enables the quantification of brain 5-HT2AR levels in humans in vivo, which has been previously associated with aspects of the psychedelic experience (<xref rid="bibr18-02698811211026454" ref-type="bibr">Ettrup et al., 2014</xref>, <xref rid="bibr19-02698811211026454" ref-type="bibr">2016</xref>; <xref rid="bibr21-02698811211026454" ref-type="bibr">Finnema et al., 2014</xref>; <xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>; <xref rid="bibr75-02698811211026454" ref-type="bibr">Stenbæk et al., 2020</xref>). Combining [<sup>11</sup>C]Cimbi-36 PET with RSFC would provide insight into the neuromolecular mechanisms associated with psychedelic effects on brain connectivity.</p>
      <p>In the current study, we evaluated the effect of a single psilocybin dose on RSFC in 10 healthy psychedelic-naïve individuals at 1 week and 3 months after administration, evaluating changes in within- and between-network RSFC. Further, we sought to replicate a previous finding of changes in region-to-region RSFC (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>). Lastly, in an exploratory analysis, we assessed correlations between network RSFC change and variables associated with increased well-being. These included personality measures, well-being and mindfulness, which we recently showed were altered 3 months after psilocybin, as well as correlated with change in the neocortex 5-HT2A binding (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>). Additionally, the baseline neocortex 5-HT2A binding was related to the temporal character of the psychedelic experience (<xref rid="bibr75-02698811211026454" ref-type="bibr">Stenbæk et al., 2020</xref>). Finally, we examined whether the self-reported experience was correlated with long-term changes in brain connectivity.</p>
    </sec>
    <sec sec-type="materials|methods" id="section7-02698811211026454">
      <title>Materials and methods</title>
      <sec id="section8-02698811211026454">
        <title>Participants</title>
        <p>Detailed information about participants and protocol are described in a previous study (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>) and one more study, which included these and other participants (<xref rid="bibr75-02698811211026454" ref-type="bibr">Stenbæk et al., 2020</xref>). The study was approved by the Danish Medicines Agency (EudraCT ID: 2016-004000-61, amendments: 2017014166, 2017082837, 2018023295) and by the ethics committee for the capital region of Copenhagen (journal ID: H-16028698, with amendments). The study was preregistered at ClinicalTrials.gov (identifier: NCT03289949). Six male and four female participants took part in this study (mean ± SD age = 28.3 ± 3.4 years).</p>
        <p>Participants were recruited from a list of individuals who expressed interest in participating in a psilocybin brain scanning study. After obtaining the informed consent, participants underwent screening for somatic illness, including a medical examination, an electrocardiogram (ECG), blood screening for somatic disease, and screening for psychiatric disorders using Mini International Neuropsychiatric Interview, Danish translation version 6.0.0 (<xref rid="bibr66-02698811211026454" ref-type="bibr">Sheehan et al., 1998</xref>). Exclusion criteria were: (1) present or previous primary psychiatric disease (DSM axis 1 or WHO ICD-10 diagnostic classifications) or in first-degree relatives; (2) present or previous neurological condition/disease, significant somatic condition/disease; (3) intake of drugs suspected to influence test results; (4) non-fluent Danish language skills; (5) vision or hearing impairment; (6) previous or present learning disability; (7) pregnancy; (8) breastfeeding; (9) magnetic resonance imaging (MRI) contraindications; (10) alcohol or drug abuse; (11) allergy to test drugs; (12) significant exposure to radiation within the past year (e.g. medical imaging investigations); (13) intake of QT-prolonging medication or ECG results indicative of heart disease, (14) blood donation less than 3 months before project participation; (15) bodyweight less than 50 kg; and (16) low plasma ferritin levels (&lt;12 µg/L).</p>
      </sec>
      <sec id="section9-02698811211026454">
        <title>Experimental procedures</title>
        <p><xref rid="fig1-02698811211026454" ref-type="fig">Figure 1</xref> provides an overview of the study design. Prior to inclusion, participants were informed about the study, including safety precautions and potential effects and side effects of psilocybin. Before the psilocybin session, all participants met at least one of the two staff members present on the psilocybin intervention day. A urine test was used to screen for common drugs of abuse (Rapid Response, BTNX Inc., Markham, ON, Canada) on baseline imaging days. At baseline, participants filled out questionnaires including the NEO Personality Inventory-Revised (NEO PI-R) (<xref rid="bibr14-02698811211026454" ref-type="bibr">Costa and McCrae, 2008</xref>; <xref rid="bibr70-02698811211026454" ref-type="bibr">Skovdahl-Hansen et al., 2004</xref>) and the mindfulness attention and awareness scale (MAAS) (<xref rid="bibr6-02698811211026454" ref-type="bibr">Brown and Ryan, 2003</xref>; <xref rid="bibr35-02698811211026454" ref-type="bibr">Jensen et al., 2016</xref>) and completed an magnetic resonance imaging (MRI) scan session.</p>
        <fig position="float" id="fig1-02698811211026454">
          <label>Figure 1.</label>
          <caption>
            <p>Flowchart describing study design. Note that not all data collected at a single time point was collected on a single day. Time lengths (mean ± SD) describe time between MRI scan sessions and psilocybin session.</p>
            <p>EDI: ego-dissolution inventory; MAAS: mindful attention awareness scale; MEQ: mystical experience questionnaire; MRI: magnetic resonance imaging; NEO-PI-R: revised NEO personality inventory; PEQ: persisting effects questionnaire; SDI: subjective drug intensity.</p>
          </caption>
          <graphic xlink:href="10.1177_02698811211026454-fig1" position="float"/>
        </fig>
        <p>On a separate day, open-label psilocybin sessions were conducted including two supporting psychologists familiar with effects of psilocybin, safety precautions and interpersonal support methods (<xref rid="bibr37-02698811211026454" ref-type="bibr">Johnson et al., 2008</xref>). Psilocybin was administered in the morning; a number of 3 mg capsules were taken with a glass of water to approximate dose (dose: 0.2 mg/kg (<italic toggle="yes">n</italic> = 4) and 0.3 mg/kg (<italic toggle="yes">n</italic> = 6)), considered ‘medium’ and ‘high’ doses, respectively (<xref rid="bibr30-02698811211026454" ref-type="bibr">Hasler et al., 2004</xref>). Participants listened to a standardised music playlist, adapted from one kindly provided by Prof. Roland Griffiths, Johns Hopkins Medicine. Music was played using a stereo system. Subjective drug intensity (SDI) was measured every 20 min using a 0–10 Likert scale (question: ‘How intense is your experience right now?’ 0=‘Not at all’, 10=‘Very much’). Measurements were obtained from the time of drug administration to the end of the session. Participants responded orally and the supporting psychologists noted their responses. At the end of psilocybin session days, participants completed questionnaires aimed to quantify aspects of the psychedelic experience, including the 11-dimensional altered states of consciousness (11D-ASC) questionnaire (<xref rid="bibr77-02698811211026454" ref-type="bibr">Studerus et al., 2010</xref>), the revised mystical experience questionnaire (MEQ30) (<xref rid="bibr3-02698811211026454" ref-type="bibr">Barrett et al., 2015</xref>), and the ego-dissolution inventory (EDI) (<xref rid="bibr54-02698811211026454" ref-type="bibr">Nour et al., 2016</xref>) (median [range]: 6.4 [5.9–7.4] h after psilocybin intake). One week and 3 months after psilocybin administration, participants returned for MRI scan sessions identical to the baseline scan session. At 3 months, participants filled out questionnaires including the NEO PI-R, MAAS and persisting effects questionnaire (PEQ) (<xref rid="bibr28-02698811211026454" ref-type="bibr">Griffiths et al., 2006</xref>, <xref rid="bibr27-02698811211026454" ref-type="bibr">2011</xref>), which measures psychological changes (both positive and negative) that are subjectively perceived to be due to the psilocybin experience. Number of days between psilocybin sessions and follow-up questionnaires: mean (SD) [range] = 97.8 (11.9) [79–120 days]).</p>
      </sec>
      <sec id="section10-02698811211026454">
        <title>Positron emission tomography</title>
        <p>The PET data used in this analysis are the same as those reported previously (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>; <xref rid="bibr75-02698811211026454" ref-type="bibr">Stenbæk et al., 2020</xref>). For a more in-depth description of the PET methods, please refer <xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al. (2020)</xref>. [<sup>11</sup>C]Cimbi-36 is an agonist radioligand selective for serotonin (5-HT) 2A (5-HT2AR) and 2C receptors (<xref rid="bibr18-02698811211026454" ref-type="bibr">Ettrup et al., 2014</xref>). Participants completed 120-min scans on a high-resolution research tomograph (HRRT) PET-scanner (CTI/Siemens, Knoxville, TN, USA) at baseline and 1 week following psilocybin administration. Regional time-activity curves were extracted using Pvelab (<xref rid="bibr79-02698811211026454" ref-type="bibr">Svarer et al., 2005</xref>) from a neocortex and cerebellum region for estimation of non-displaceable binding potential (BPND) using the simplified reference tissue model (<xref rid="bibr19-02698811211026454" ref-type="bibr">Ettrup et al., 2016</xref>; <xref rid="bibr34-02698811211026454" ref-type="bibr">Innis et al., 2007</xref>). Neocortex [<sup>11</sup>C]Cimbi-36 binding predominantly reflects 5-HT2AR binding (<xref rid="bibr21-02698811211026454" ref-type="bibr">Finnema et al., 2014</xref>). The neocortex and cerebellum regions of interest (ROIs) were defined a priori in Pvelab (<xref rid="bibr79-02698811211026454" ref-type="bibr">Svarer et al., 2005</xref>). The neocortex ROI comprises occipital, orbitofrontal and parietal cortex as well as pre/post central, middle/inferior frontal, middle/inferior temporal, superior frontal and superior temporal gyri. A composite neocortex ROI was used because the signal is very highly correlated between these regions (<xref rid="bibr74-02698811211026454" ref-type="bibr">Spies et al., 2020</xref>). Subcortical [<sup>11</sup>C]Cimbi-36 binding was not considered because the signal is low and noisy. The cerebellum ROI encompasses only the grey matter of the cerebellum.</p>
      </sec>
      <sec id="section11-02698811211026454">
        <title>Magnetic resonance imaging scan parameters</title>
        <p>Participants completed three identical MRI scan sessions: baseline, 1-week, and 3-month post-psilocybin. The MRI data were acquired on a 3T Prisma scanner (Siemens, Erlangen, Germany) using a 64-channel head/neck coil. A high-resolution 3D T1-weighted structural image was acquired: inversion time = 900 ms, echo time = 2.58 ms, repetition time = 1900 ms, flip angle = 9°, in-plane matrix = 256 × 256, in-plane resolution = 0.9 × 0.9 mm, 224 slices, and a slice thickness of 0.9 mm, no gap. Ten minutes of resting-state BOLD fMRI data was acquired: repetition time = 2000 ms, echo time = 30 ms, flip angle = 90°, 32 axial slices with a slice thickness of 3 mm, 0.75 mm gap, in-plane resolution: 3.6 × 3.6 mm, iPAT acceleration factor = 2. A gradient-echo field map of the same spatial dimensions was acquired to resolve spatial distortions due to inhomogeneities in the magnetic field (repetition time = 400 ms, echo times = 4.92 and 7.38 ms). Prior to the resting-state scan sessions, participants were instructed to close their eyes, let their mind wander freely and to not to fall asleep. Resting-state scan sessions were acquired after structural image acquisition (~15–20 min after scanning onset) and prior to task-related fMRI measures not described here.</p>
      </sec>
      <sec id="section12-02698811211026454">
        <title>Resting-state fMRI pre-processing</title>
        <p>Resting-state fMRI data were pre-processed using SPM12 (<xref rid="bibr57-02698811211026454" ref-type="bibr">Penny et al., 2007</xref>). This process included slice-timing correction, realignment and unwarping, co-registration of the high-resolution T1 structural image to the fMRI data, segmentation of the high-resolution T1 structural image, applying warping parameters estimated for the high-resolution T1 into MNI space to fMRI data and smoothing with an 8-mm full width at half maximum (FWHM) Gaussian filter. Additional denoising of time-series data was performed using CONN (version 17.c) (<xref rid="bibr83-02698811211026454" ref-type="bibr">Whitfield-Gabrieli and Nieto-Castanon, 2012</xref>). Time series were filtered using a bandpass filter from 0.008 to 0.09 Hz. Additionally, we performed an estimation of physiological noise sources using anatomical component correction (aCompCor): regressing out the time series (and first derivative) of the first five principal components from a decomposition of the time series from white-matter and cerebrospinal fluid voxels, separately. Additionally, we regressed the time series for the six motion parameters (and first derivatives) (<xref rid="bibr4-02698811211026454" ref-type="bibr">Behzadi et al., 2007</xref>; <xref rid="bibr83-02698811211026454" ref-type="bibr">Whitfield-Gabrieli and Nieto-Castanon, 2012</xref>). Individual outlier volumes were identified and censored using the Artifact Detection Tools (ART) (global variance threshold = 4 and composite motion threshold = 2) (<ext-link xlink:href="http://web.mit.edu/swg/software.htm" ext-link-type="uri">http://web.mit.edu/swg/software.htm</ext-link>). Mean denoised time series were extracted from ROIs for further analysis. We calculated the between-region correlation across the entire time series. The Pearson’s rho correlation estimates were transformed using Fisher’s <italic toggle="yes">r</italic>-to-<italic toggle="yes">z</italic> transform (i.e. <italic toggle="yes">r</italic>-to-<italic toggle="yes">z</italic> = 0.5 × (ln((1+<italic toggle="yes">r</italic>)/(1−<italic toggle="yes">r</italic>))), where <italic toggle="yes">r</italic> is the Pearson’s rho and <italic toggle="yes">ln</italic> represent taking the natural logarithm). These <italic toggle="yes">r</italic>-to-<italic toggle="yes">z</italic> values were included in the statistical analyses related to the connectivity strength.</p>
      </sec>
      <sec id="section13-02698811211026454">
        <title>Brain atlases</title>
        <p>Regions of interest and networks were defined using an a priori defined atlas (<xref rid="bibr61-02698811211026454" ref-type="bibr">Raichle, 2011</xref>)⁠. This atlas defines 36 regions belonging to seven canonical resting-state networks: network (DMN), dorsal attention network (DAN), executive control network (ECN), salience network (SN), sensorimotor network (SMN), visual network (VN) and auditory network (AN). Montreal Neurological Institute (MNI) coordinates for each network can be found in <xref rid="bibr61-02698811211026454" ref-type="bibr">Raichle (2011)</xref> and in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811211026454" ext-link-type="uri">Supplemental Table S1</ext-link>. Within-network connectivity was defined as the mean connectivity between each unique pair of ROIs comprising a given network. Henceforth ECN integration and disintegration refer to increased and decreased mean within-network connectivity, respectively. Between-network connectivity was defined as the mean connectivity between all ROIs from two networks, where each pair of ROIs contained a region from each network. To draw comparisons with a similar previous study, we also evaluated a 268-region atlas (<ext-link xlink:href="https://www.nitrc.org/frs/?" ext-link-type="uri">https://www.nitrc.org/frs/?</ext-link>group_id=51) described previously (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>; <xref rid="bibr69-02698811211026454" ref-type="bibr">Shen et al., 2013</xref>).</p>
      </sec>
      <sec id="section14-02698811211026454">
        <title>Statistical analysis</title>
        <p>All statistical analyses were calculated in R (v4.0.2) (<xref rid="bibr60-02698811211026454" ref-type="bibr">R Studio Team, 2020</xref>). Plots were constructed using the <italic toggle="yes">ggplot2</italic> package (<xref rid="bibr84-02698811211026454" ref-type="bibr">Wickham, 2016</xref>).</p>
        <p>Paired <italic toggle="yes">t</italic>-tests were performed to investigate if there were any significant differences in ART censored volumes between time points (1 week vs. 3 months). Effects of time (1 week vs. baseline or 3 months vs. baseline) were compared separately using paired <italic toggle="yes">t</italic>-tests to determine the effect of time on within- and between-network connectivity and related estimates. The <italic toggle="yes">p</italic>-values across the 28 within- and between-network comparisons at each time point were adjusted using the Bonferroni–Holm method, which controls the family-wise type-I error rate (<xref rid="bibr31-02698811211026454" ref-type="bibr">Holm, 1979</xref>). Unadjusted <italic toggle="yes">p</italic>-values are denoted <italic toggle="yes">p</italic><sub>unc</sub>, whereas adjusted <italic toggle="yes">p</italic>-values are denoted <italic toggle="yes">p</italic><sub>FWE</sub>. Where an effect of psilocybin on connectivity exceeded our statistical significance threshold (p<sub>FWE</sub> &lt; 0.05), exploratory post hoc analyses were performed. We report the Cohen’s <italic toggle="yes">d</italic> value for each post hoc effect evaluated. Due to limited statistical power stemming from a small sample, we do not draw inference on statistical significance for post hoc analyses, but instead report standardised effect sizes and 95% confidence intervals.</p>
        <sec id="section15-02698811211026454">
          <title>Correlations</title>
          <p>The post hoc Pearson’s product–moment correlations were performed between change in ECN connectivity and change in MAAS, change in neocortex 5-HT2AR (i.e. [<sup>11</sup>C]Cimbi-36 BP<sub>ND</sub>) (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>) as well as measures of the acute psychedelic experience (SDI, EDI, MEQ and 11-D-ASC) and change in personality (NEO-PIR). Change in ECN RSFC was also compared with the PEQ using a linear latent variable model capturing shared covariance in individual behavioural change measures using the <italic toggle="yes">lava</italic> package (v. 1.6.8 in R (<xref rid="bibr32-02698811211026454" ref-type="bibr">Holst and Budtz-Jørgensen, 2013</xref>)).</p>
        </sec>
        <sec id="section16-02698811211026454">
          <title>Barrett replication analysis</title>
          <p>We attempted to replicate a previously described analysis framework applied to the Shen268 atlas (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>). As described, we applied a one-sample <italic toggle="yes">t</italic>-test to all ROI-to-ROI connectivity estimates and retained only those edges with a statistically significant non-zero mean connectivity after the Bonferroni correction for 35,778 edges tested at each time point (i.e. <italic toggle="yes">p</italic><sub>unc</sub> &lt; 1.4 × 10<sup>−6</sup>). Paired <italic toggle="yes">t</italic>-tests evaluating change from baseline at 1 week or 3 months were performed for each edge surviving correction. Suprathreshold edges were identified as either increases or decreases in connectivity following psilocybin.</p>
          <p>In our view, the type-I error for the test of interest (i.e. effect of psilocybin) is inflated by the initial ‘edge filtering’ step considering each time point separately and further inflated by not adjusting for the family of tests of interest (695 reported in <xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>). Accordingly, we report paired <italic toggle="yes">t</italic>-tests evaluating changes from baseline to 1 week or 3 months, adjusting <italic toggle="yes">p</italic>-values using the Bonferroni–Holm method for the set of edges tested.</p>
          <p>The R Notebook containing code used in the production of this manuscript is available at <ext-link xlink:href="https://github.com/Pneumaethylamine/LastingPsilocybinRSFC" ext-link-type="uri">https://github.com/Pneumaethylamine/LastingPsilocybinRSFC</ext-link></p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="results" id="section17-02698811211026454">
      <title>Results</title>
      <sec id="section18-02698811211026454">
        <title>Population</title>
        <p>Acute psychedelic effects were well tolerated in all participants, and no serious adverse events occurred. Based on self-report SDI scores throughout the sessions, the psychedelic experiences were characterised by three distinct phases, the onset, peak plateau and descent (<xref rid="bibr75-02698811211026454" ref-type="bibr">Stenbæk et al., 2020</xref>). As previously reported, participants in this study self-reported changes in personality, including increased trait openness and mindfulness (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>). Self-reported increases in positive attributes from the PEQ (including spirituality) were 25.9% ± 21.5% (mean ± SD), whereas increased negative attributes reported were 1.4% ± 1.7%. Time between baseline and psilocybin intervention was 15.3 ± 9.3 days, intervention and 1 week rescan was 6.5 ± 1.4 days and intervention and 3 month rescan was 101.5 ± 9.9 days (mean ± SD).</p>
      </sec>
      <sec id="section19-02698811211026454">
        <title>Lasting psilocybin effects on network connectivity</title>
        <p>Within- and between-network RSFC structure was as expected, for example, high within-network connectivity and relatively lower between-network connectivity (<xref rid="fig2-02698811211026454" ref-type="fig">Figure 2(a)</xref>). Mean composite motion and censored volumes were low (3.5 ± 4.0 volumes; mean ± SD) and not statistically significantly different between scan times (<italic toggle="yes">p</italic><sub>unc</sub> &gt; 0.05).</p>
        <fig position="float" id="fig2-02698811211026454">
          <label>Figure 2.</label>
          <caption>
            <p>Psilocybin effects on within- and between-network resting-state connectivity: (a) mean within- and between-network functional connectivity, cell values and colour scale represent mean <italic toggle="yes">r</italic>-to-<italic toggle="yes">z</italic> values across participants, (b) change in connectivity from baseline to 1-week rescan, (c) change in connectivity from baseline to 3 month rescan. Cell values and colour scale in (b) and (c) represent effect size (Cohen’s <italic toggle="yes">d</italic>).</p>
            <p>* denotes change that is statistically significant after adjustment across 28 tests (i.e. pFWE &lt; 0.05).</p>
          </caption>
          <graphic xlink:href="10.1177_02698811211026454-fig2" position="float"/>
        </fig>
        <p>ECN within-network connectivity was statistically significantly decreased at 1 week (<italic toggle="yes">p</italic><sub>unc</sub> = 0.00039, <italic toggle="yes">p</italic><sub>FWE</sub> = 0.010, Cohen’s <italic toggle="yes">d</italic> = −1.73; <xref rid="fig2-02698811211026454" ref-type="fig">Figures 2(b)</xref> and <xref rid="fig3-02698811211026454" ref-type="fig">3</xref>). Nine of 10 participants showed numerically reduced ECN RSFC at 1 week. Examination of individual ECN edges showed that nine of 10 edges had decreased connectivity across the 10 participants. At 3 months, ECN RSFC remained numerically decreased as compared to baseline, but this effect was not statistically significant (<italic toggle="yes">p</italic><sub>unc</sub> = 0.23, <italic toggle="yes">p</italic><sub>FWE</sub> = 1, Cohen’s <italic toggle="yes">d</italic> = −0.4). No other within- or between-network connectivity estimates were statistically significantly altered at 1 week or 3 months (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811211026454" ext-link-type="uri">Supplemental Table S2</ext-link>). Additional network connectivity effects with a |Cohen’s <italic toggle="yes">d</italic>| &gt; 0.5 include at 1 week, SMN–SMN, ECN–VN and DAN–AN connectivity decreased (Cohen’s <italic toggle="yes">d</italic> = −0.6), whereas DMN–ECN connectivity increased (Cohen’s <italic toggle="yes">d</italic> = 0.5). At 3 months, ECN–VN and DAN–AN connectivity remained decreased (Cohen’s <italic toggle="yes">d</italic> = −0.6 and −0.5, respectively). A Cohen’s <italic toggle="yes">d</italic> magnitude &gt;0.5 represents a ‘medium’ effect size (<xref rid="bibr20-02698811211026454" ref-type="bibr">Ferguson, 2009</xref>).</p>
        <fig position="float" id="fig3-02698811211026454">
          <label>Figure 3.</label>
          <caption>
            <p>Executive control network (ECN) connectivity by participant. Spaghetti plot showing individual changes in mean ECN connectivity scores (y-axis) and time point (x-axis). Error bars represent mean ± standard deviation. Colours represent individual participants. ECN connectivity is significantly decreased at 1 week but not at 3 months.</p>
          </caption>
          <graphic xlink:href="10.1177_02698811211026454-fig3" position="float"/>
        </fig>
      </sec>
      <sec id="section20-02698811211026454">
        <title>Replication of previous study</title>
        <p>Later, we attempted to replicate previously reported findings from a similar study (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>). Of the 35,778 edges defined by the Shen268 atlas, 405 showed evidence for significant connectivity based on the strategy described by Barrett and colleagues, who reported 695 suprathreshold edges. RSFC was altered in 25 edges at 1 week (19 increased and six decreased) and 18 edges at 3 months (12 increased and six decreased) at a statistical threshold of <italic toggle="yes">p</italic><sub>unc</sub> &lt; 0.05. Two of these edges were altered in the same direction at both time points (one increased and one decreased). Although we observed fewer total edges showing evidence for significant connectivity, we observed a similar proportion of edges showing a time effect (i.e. 25/405 and 18/405 are approximately similar to 48/695 and 29/695, respectively). None of the 25 nor 18 edges remained statistically significant after controlling the type-I error for the 405 tests using the Bonferroni–Holm method.</p>
      </sec>
      <sec id="section21-02698811211026454">
        <title>Exploratory associations with ECN functional connectivity</title>
        <p>Lastly, we explored the association between change in ECN RSFC at 1 week and self-report measures of the psychedelic experience acquired immediately after the experience, change in neocortex 5-HT2AR (at 1 week), change in personality (at 3 months) and self-reported persisting effects of the psychedelic experience (3 months). A summary of correlations can be found in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811211026454" ext-link-type="uri">Supplemental Table S3</ext-link>.</p>
        <p>The most promising associations were observed between changes in ECN functional connectivity at 1 week and 3 months with self-reported change in MAAS at 3 months (<italic toggle="yes">r</italic> [95% CI] = −0.65 [−0.91, −0.04]) and (<italic toggle="yes">r</italic> [95% CI] = 0.71 [0.15, 0.93]) respectively, that is, the greater the decrease in ECN connectivity at 1 week, the greater the increase in MAAS score at 3 months (<xref rid="fig4-02698811211026454" ref-type="fig">Figure 4</xref>). A smaller ECN connectivity change from baseline to 3 months was associated with a greater increase in MAAS score.</p>
        <fig position="float" id="fig4-02698811211026454">
          <label>Figure 4.</label>
          <caption>
            <p>Correlations between executive control network (ECN) connectivity and mindful attention awareness scale (MAAS). Scatter plots with linear regressions between MAAS score (<italic toggle="yes">y</italic>-axis) and (a) change in ECN connectivity at 1 week, and (b) change in ECN connectivity at 3 months. Blue lines represent lines of best fit and black dots denote observed data.</p>
          </caption>
          <graphic xlink:href="10.1177_02698811211026454-fig4" position="float"/>
        </fig>
        <sec id="section22-02698811211026454">
          <title>Neocortex 5-HT2AR</title>
          <p>Change in neocortex 5-HT2AR binding measured with [<sup>11</sup>C]Cimbi-36 BP<sub>ND</sub> at 1 week was not correlated with change in ECN connectivity at 1 week (<italic toggle="yes">r</italic> [95% CI] = 0.52 [−0.15, 0.87]). However, change in neocortex 5-HT2AR at 1 week correlated more strongly with the ECN RSFC change at 3 months (<italic toggle="yes">r</italic> [95% CI] = −0.67 [−0.91, −0.06]). In other words, greater disintegration of the ECN correlated with more neocortex 5-HT2AR.</p>
        </sec>
        <sec id="section23-02698811211026454">
          <title>Persisting effects questionnaire</title>
          <p>The positive subscales of the PEQ loaded strongly onto a single latent construct, indicating high shared correlation (<italic toggle="yes">p</italic> &lt; 10<sup>−6</sup>). Change in ECN RSFC at 1 week was negatively associated with the underlying latent variable (−19.9 [−41.7, 1.93], units: change in Life Positivity PEQ per 0.1-unit change in ECN RSFC; <xref rid="fig5-02698811211026454" ref-type="fig">Figure 5</xref>). Individual estimates are reported in <xref rid="fig5-02698811211026454" ref-type="fig">Figure 5</xref>.</p>
          <fig position="float" id="fig5-02698811211026454">
            <label>Figure 5.</label>
            <caption>
              <p>Linear latent variable model linking change in executive control network (ECN) connectivity at 1 week and persisting effects questionnaire (PEQ) responses at 3 months. The green box denotes observed change in ECN connectivity at 1 week. The red box denotes the latent variable (‘positive drug change’). The yellow boxes denote observed PEQ scores. Hatched orange lines between ‘mood-positivity’ and ‘altruism’ indicate additional shared covariance. Hatched lines denote model components estimated with error. The loading parameter, β, reflecting the correlation of the score with the latent variable for each model path is noted in respective boxes (95% confidence intervals indicated for estimates between latent variable and PEQ subscale scores). Significance of the estimated effect of the ECN change on the latent variable is also noted.</p>
            </caption>
            <graphic xlink:href="10.1177_02698811211026454-fig5" position="float"/>
          </fig>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion" id="section24-02698811211026454">
      <title>Discussion</title>
      <p>Our results show that psilocybin, when administered to healthy volunteers in a controlled environment, statistically significantly decreases ECN RSFC at 1 week, but not at 3 months. We observed correlations between ECN RSFC changes and changes in MAAS, neocortex 5-HT2AR and positive aspects of the PEQ, implicating alterations in ECN connectivity as a potential mechanism underlying the clinical and behavioural effects of psilocybin. No other network connectivity estimates were statistically significantly affected at 1 week or 3 months. Our study is small, but nevertheless implicates a candidate brain system underlying lasting psilocybin effects that can be examined in future studies in healthy and patient populations.</p>
      <sec id="section25-02698811211026454">
        <title>Executive control network connectivity</title>
        <p>A single psilocybin administration decreased ECN RSFC; nine out of 10 participants showed decreased ECN RSFC and nine out of 10 ECN edges showed decreased RSFC across all participants. This distributed effect is consistent with this representing a network-wide effect not driven by a specific participant or edge. Executive functions include, for example, cognitive flexibility, goal setting, attentional control and information processing (<xref rid="bibr52-02698811211026454" ref-type="bibr">Niendam et al., 2012</xref>). This is consistent with qualitative reports in addiction patients who report persistent changes in attentional control and goal setting following psilocybin intervention (<xref rid="bibr51-02698811211026454" ref-type="bibr">Nielson et al., 2018</xref>; <xref rid="bibr53-02698811211026454" ref-type="bibr">Noorani et al., 2018</xref>). Though little research has been performed on ECN RSFC and its association with trait changes in executive functions, one study reported lower FC within the ECN in long-term tai-chi practitioners relative to controls. These practitioners also showed increased trait mindfulness and performed better on emotion regulation tasks (<xref rid="bibr41-02698811211026454" ref-type="bibr">Liu et al., 2018</xref>), aligning with our finding that decreased ECN connectivity predicted increased trait mindfulness. Change in ECN connectivity was not associated with any measures of the acute experience (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811211026454" ext-link-type="uri">Supplemental Table S3</ext-link>), suggesting it might not simply be mediated by brain psilocin concentration (<xref rid="bibr43-02698811211026454" ref-type="bibr">Madsen et al., 2019</xref>).</p>
        <p>Psilocybin has been shown in small open-label trials to be efficacious in the treatment of depression (Cohen’s <italic toggle="yes">d</italic> = −2.1 and −2.5 at 5-week post-administration) (<xref rid="bibr9-02698811211026454" ref-type="bibr">Carhart-Harris et al., 2018</xref>; <xref rid="bibr15-02698811211026454" ref-type="bibr">Davis et al., 2020</xref>), a disorder, which is partly characterised by deficits in executive functions (<xref rid="bibr73-02698811211026454" ref-type="bibr">Snyder, 2013</xref>). Our finding that psilocybin decreased ECN RSFC is consistent with a recent study reporting that unmedicated, first-time MDD patients demonstrated hyper-connectivity between the left dorsolateral prefrontal cortex (PFC) and frontal and parietal regions, nodes which commonly constitute cognitive control networks (<xref rid="bibr68-02698811211026454" ref-type="bibr">Shen et al., 2015</xref>). However, another study reported that MDD is characterised by reduced frontoparietal control system connectivity (<xref rid="bibr38-02698811211026454" ref-type="bibr">Kaiser et al., 2015</xref>). Although it is intriguing that in healthy individuals we observe an effect of psilocybin on a resting-state network that displays pathological connectivity in depressed patients, future studies are necessary to more clearly establish this network’s relation to treatment-induced changes in measures of personality and well-being. Additionally, it remains to be established whether psilocybin-induced changes in connectivity would produce the well-being states described by such connectivity signatures in healthy, untreated individuals.</p>
        <p>The observed effect on ECN RSFC may also align with psilocybin’s potential effects on obsessive-compulsive disorder (OCD) (<xref rid="bibr47-02698811211026454" ref-type="bibr">Moreno et al., 2006</xref>) and addiction (<xref rid="bibr5-02698811211026454" ref-type="bibr">Bogenschutz et al., 2015</xref>; <xref rid="bibr36-02698811211026454" ref-type="bibr">Johnson et al., 2017</xref>), disorders broadly characterised by aberrant control of behaviour. The OCD patients display greater connectivity in ECN regions, including dorsolateral PFC (<xref rid="bibr13-02698811211026454" ref-type="bibr">Chen et al., 2016</xref>), suggesting that reducing ECN connectivity could be therapeutically beneficial. Although individuals with addiction disorder show neuropsychological impairment in brain regions associated with cognitive control (<xref rid="bibr25-02698811211026454" ref-type="bibr">Goldstein et al., 2004</xref>), RSFC investigations of control networks in addiction have so far utilised alternative network definitions, and thus are not directly comparable to these findings (<xref rid="bibr78-02698811211026454" ref-type="bibr">Sutherland et al., 2012</xref>).</p>
        <p>As we only see a significant change in ECN connectivity at 1 week and not at 3 months, this change may underlie the ‘afterglow’ effect. Despite the lack of long-term effects, the association between the 1 week effect and long-term measures of well-being suggests a role for this period in mediating long-term effects on well-being, the neural correlates of which were not detected in this study. Detailed quantitative characterisation of the ‘afterglow’ phenomenon could enable optimisation around this potentially clinically important phase of psychedelic psychotherapy by, for example, informing best practice surrounding post-session integration.</p>
      </sec>
      <sec id="section26-02698811211026454">
        <title>Additional effects on connectivity</title>
        <p>Besides ECN RSFC at 1 week, all other standardised effect sizes for psilocybin induced change in RSFC (within- and between-network) were small to medium (i.e. |Cohen’s <italic toggle="yes">d</italic>| &lt; 0.5). This suggests that future studies evaluating similar effects of psilocybin on RSFC would require sample sizes &gt;60 to be adequately statistically powered (i.e. (1−β) &gt; 0.8). Thus, our findings argue against large-scale changes in network connectivity structure insofar as we have quantified them here. This is notable considering participants report substantive changes in personality and well-being lasting for at least 1 year (<xref rid="bibr17-02698811211026454" ref-type="bibr">Erritzoe et al., 2018</xref>; <xref rid="bibr42-02698811211026454" ref-type="bibr">MacLean et al., 2011</xref>; <xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>) that are likely not entirely explained by ECN changes.</p>
        <p>Our results suggest a small effect of psilocybin on DMN RSFC (Cohen’s <italic toggle="yes">d</italic> = 0.19). This is noteworthy because DMN disintegration has been reported when scanning participants during the psychedelic experience (<xref rid="bibr10-02698811211026454" ref-type="bibr">Carhart-Harris et al., 2012</xref>; <xref rid="bibr59-02698811211026454" ref-type="bibr">Preller et al., 2020</xref>) and may be implicated in the therapeutic effects of psilocybin as DMN connectivity is elevated in a range of conditions and is reduced following administration of psilocybin to experienced meditators (<xref rid="bibr72-02698811211026454" ref-type="bibr">Smigielski et al., 2019</xref>; <xref rid="bibr82-02698811211026454" ref-type="bibr">Whitfield-Gabrieli and Ford, 2012</xref>). Although we do not see a persistent effect on DMN connectivity, acute disruption of the DMN may still be therapeutically relevant (<xref rid="bibr8-02698811211026454" ref-type="bibr">Carhart-Harris and Friston, 2019</xref>; <xref rid="bibr46-02698811211026454" ref-type="bibr">Mason et al., 2020</xref>). Intake of both Salvinorin-A, a 5-HT2AR-independent hallucinogen, and 3,4-methylenedioxymethamphetamine (MDMA), which has a subjective effect profile distinct from serotonergic psychedelics (<xref rid="bibr16-02698811211026454" ref-type="bibr">Doss et al., 2020</xref>; <xref rid="bibr48-02698811211026454" ref-type="bibr">Müller et al., 2020</xref>; <xref rid="bibr63-02698811211026454" ref-type="bibr">Roseman et al., 2014</xref>), leads to a reduction in DMN connectivity. Reduced DMN connectivity is not associated with ego-dissolution in response to psilocybin (<xref rid="bibr39-02698811211026454" ref-type="bibr">Lebedev et al., 2015</xref>). This muted effect on DMN RSFC after the psychedelic session is consistent with a study that scanned MDD individuals 1 day after the psychedelic experience (<xref rid="bibr12-02698811211026454" ref-type="bibr">Carhart-Harris et al., 2017</xref>) and healthy volunteers 1 week and 1 month after psilocybin (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>). Thus, convergent evidence indicates that persistent alterations in DMN RSFC are unlikely to be a critical mechanism underlying lasting psilocybin effects.</p>
      </sec>
      <sec id="section27-02698811211026454">
        <title>Associations with executive control network change</title>
        <p>Through exploratory analyses, we observed three notable associations with change in ECN RSFC. Firstly, a greater decrease in ECN RSFC at 1 week and a lesser decrease in ECN RSFC at 3 months both correlated with increased mindfulness score at 3 months. This could reflect that ECN disintegration followed by reintegration produces lasting increases in mindful awareness, a trait that is associated with reduced stress and better mood (<xref rid="bibr6-02698811211026454" ref-type="bibr">Brown and Ryan, 2003</xref>). Secondly, building on our previous finding that change in 5-HT2AR correlated negatively with change in mindfulness (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>), we observed that a greater decrease in ECN RSFC 1 week and a lesser decrease in ECN RSFC at 3 months was associated with decreased 5-HT2AR at 1 week. Although speculative, our findings suggest that individual change in neocortex 5-HT2AR following psilocybin administration may effect a change in mindfulness that is mediated by changes in ECN connectivity. Thirdly, decrease in ECN at 1 week was positively associated with a latent construct of positive persisting effects, reflecting positive items from the PEQ, at 3 months. This effect was particularly pronounced regarding ‘behavioural positivity’, aligning with qualitative reports from patients in clinical trials (<xref rid="bibr51-02698811211026454" ref-type="bibr">Nielson et al., 2018</xref>; <xref rid="bibr53-02698811211026454" ref-type="bibr">Noorani et al., 2018</xref>). Although exploratory, these observations provide a framework for linking brain and behavioural changes effected by psilocybin administration in future studies in healthy and clinical cohorts. Although we see changes in personality-trait openness, neuroticism and conscientiousness in this sample (<xref rid="bibr44-02698811211026454" ref-type="bibr">Madsen et al., 2020</xref>), these changes were not correlated with change in ECN RSFC (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811211026454" ext-link-type="uri">Supplemental Table S3</ext-link>).</p>
      </sec>
      <sec id="section28-02698811211026454">
        <title>Barrett replication</title>
        <p>Replication is critical for identifying reliable brain markers of psilocybin effects. Here, we sought to replicate recently reported findings from a study very similar to ours (<xref rid="bibr2-02698811211026454" ref-type="bibr">Barrett et al., 2020</xref>). We replicated the scale of region-to-region RSFC estimates that were affected by psilocybin. However, none of these effects remained statistically significant when controlling for multiple comparisons. Ours and the previous study have small sample sizes, which exacerbate the statistical power limitations of an exploratory region-to-region RSFC analysis strategy. Without substantively larger samples, this analysis framework would likely benefit from a hypothesis-driven evaluation of specific region pairs. Notably, the Shen268 atlas does not describe an ECN, and thus these results cannot be compared with our ECN finding using the Raichle atlas. This heterogeneity highlights a case for co-ordination of spatial parcellation within this corner of neuroimaging.</p>
      </sec>
      <sec id="section29-02698811211026454">
        <title>Limitations</title>
        <p>As noted previously, our sample size of 10 individuals limits statistical power. Nevertheless, the data reported here provide a firmer foundation for future studies in clinical and healthy cohorts with larger samples. Although psilocybin seems to have positive behavioural and mood effects in healthy individuals, it is not clear how closely our observed effects on brain connectivity would generalise to clinical cohorts. Additional studies in patient groups are needed to delineate the neurobiological basis of therapeutic effects of serotonergic psychedelics including psilocybin. There is variation across resting-state atlases in how cognitive control networks are defined, limiting our ability to draw firm conclusions with previous related studies (<xref rid="bibr62-02698811211026454" ref-type="bibr">Raichle, 2015</xref>; <xref rid="bibr65-02698811211026454" ref-type="bibr">Schaefer et al., 2018</xref>; <xref rid="bibr67-02698811211026454" ref-type="bibr">Shen et al., 2020</xref>). Alternative analytic strategies (e.g. dynamic functional connectivity and entropy analyses) or task-based fMRI may reveal more pronounced effects on brain function and connectivity than those reported here. Future studies integrating fMRI with PET markers may offer deeper insights into the neurobiological mechanisms mediating psilocybin effects on behaviour (<xref rid="bibr22-02698811211026454" ref-type="bibr">Fisher and Hariri, 2012</xref>). Although the observed effect on ECN may be related to individual differences in pharmacodynamics (i.e. drug availability and metabolism), we did not measure individual plasma psilocin levels (<xref rid="bibr43-02698811211026454" ref-type="bibr">Madsen et al., 2019</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="section30-02698811211026454">
      <title>Conclusion</title>
      <p>In conclusion, we report effects of a single psilocybin administration on RSFC networks at 1 week and 3 months in a cohort of 10 individuals. Although a small sample, we identified a statistically significant reduction in ECN RSFC at 1 week but not at 3 months (although numerically decreased). Exploratory correlations with change in ECN at 1 week suggest that it may be associated with change in neocortex 5-HT2AR at 1 week as well as change in mindfulness and persistent positive psychological effects at 3 months. Nevertheless, future studies are necessary to more thoroughly map psilocybin effects on to changes in brain function and connectivity that may mediate its lasting clinical and behavioural effects.</p>
    </sec>
    <sec sec-type="supplementary-material" id="section31-02698811211026454" specific-use="figshare">
      <title>Supplemental Material</title>
      <supplementary-material id="suppl1-02698811211026454" position="float" content-type="local-data">
        <caption>
          <title>sj-docx-1-jop-10.1177_02698811211026454 – Supplemental material for Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals</title>
        </caption>
        <media xlink:href="sj-docx-1-jop-10.1177_02698811211026454.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
        <p>Supplemental material, sj-docx-1-jop-10.1177_02698811211026454 for Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals by Drummond E-Wen McCulloch, Martin Korsbak Madsen, Dea Siggaard Stenbæk, Sara Kristiansen, Brice Ozenne, Peter Steen Jensen, Gitte Moos Knudsen and Patrick MacDonald Fisher in Journal of Psychopharmacology</p>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>Psilocybin was kindly supplied by National Institute of Mental Health, Klecany, Czech Republic and Forensic Laboratory of Biologically Active Compounds, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement">
        <p><bold>Declaration of conflicting interests:</bold> The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DEM’s salary was supported by an unrestricted grant from COMPASS Pathways Ltd., which had no involvement in this manuscript or related data collection. GMK has received honoraria as consultant for Sanos and for Sage Therapeutics. All other authors declare that there are no conflicts of interest.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Innovation Fund Denmark (grant number: 4108-00004B), Independent Research Fund Denmark (grant number: 6110-00518B), and Ester M. og Konrad Kristian Sigurdssons Dyreværnsfond (grant number: 850-22-55166-17-LNG). MKM was supported by the Rigshospitalet Research Council (grant number: R130-A5324). BO was supported by the Lundbeck Foundation (grant number: R231-2016-3236) and Marie-Curie-NEUROMODEL (grant number: 746850). DEM was supported by an unrestricted grant from COMPASS Pathways Ltd.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>ORCID iDs:</bold> Drummond E-Wen McCulloch <inline-graphic xlink:href="10.1177_02698811211026454-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0001-6360-5224" ext-link-type="uri">https://orcid.org/0000-0001-6360-5224</ext-link></p>
        <p>Dea Siggaard Stenbæk <inline-graphic xlink:href="10.1177_02698811211026454-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-5439-4637" ext-link-type="uri">https://orcid.org/0000-0002-5439-4637</ext-link></p>
        <p>Patrick MacDonald Fisher <inline-graphic xlink:href="10.1177_02698811211026454-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-8115-0611" ext-link-type="uri">https://orcid.org/0000-0002-8115-0611</ext-link></p>
      </fn>
      <fn fn-type="supplementary-material">
        <p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>BT</given-names></name>
<name><surname>Danforth</surname><given-names>A</given-names></name>
<name><surname>Daroff</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study</article-title>. <source>EClinicalMedicine</source>
<volume>27</volume>: <publisher-name>100538</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100538.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Barrett</surname><given-names>FS</given-names></name>
<name><surname>Doss</surname><given-names>MK</given-names></name>
<name><surname>Sepeda</surname><given-names>ND</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Emotions and brain function are altered up to one month after a single high dose of psilocybin</article-title>. <source>Sci Rep</source>
<volume>10</volume>: <year>2214</year>. DOI: <pub-id pub-id-type="doi">10.1038/s41598-020-59282-y.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Barrett</surname><given-names>FS</given-names></name>
<name><surname>Johnson</surname><given-names>MW</given-names></name>
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
</person-group> (<year>2015</year>) <article-title>Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin</article-title>. <source>J Psychopharmacol</source>
<volume>29</volume>: <fpage>1182</fpage>–<lpage>1190</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881115609019.</pub-id><pub-id pub-id-type="pmid">26442957</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Behzadi</surname><given-names>Y</given-names></name>
<name><surname>Restom</surname><given-names>K</given-names></name>
<name><surname>Liau</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2007</year>) <article-title>A component based noise correction method (CompCor) for BOLD and perfusion based fMRI</article-title>. <source>NeuroImage</source>
<volume>37</volume>: <fpage>90</fpage>–<lpage>101</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.04.042.</pub-id><pub-id pub-id-type="pmid">17560126</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bogenschutz</surname><given-names>MP</given-names></name>
<name><surname>Forcehimes</surname><given-names>AA</given-names></name>
<name><surname>Pommy</surname><given-names>JA</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2015</year>) <article-title>Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study</article-title>. <source>J Psychopharmacol</source>
<volume>29</volume>: <fpage>289</fpage>–<lpage>299</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881114565144.</pub-id><pub-id pub-id-type="pmid">25586396</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>KW</given-names></name>
<name><surname>Ryan</surname><given-names>RM</given-names></name>
</person-group> (<year>2003</year>) <article-title>The benefits of being present: Mindfulness and its role in psychological well-being</article-title>. <source>J Pers Soc Psychol</source>
<volume>84</volume>: <fpage>822</fpage>–<lpage>848</lpage>. DOI: <pub-id pub-id-type="doi">10.1037/0022-3514.84.4.822.</pub-id><pub-id pub-id-type="pmid">12703651</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cai</surname><given-names>H</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>Y</given-names></name>
</person-group> (<year>2020</year>) <article-title>Robust prediction of individual personality from brain functional connectome</article-title>. <source>Soc Cogn Affect Neurosci</source>
<volume>15</volume>: <fpage>359</fpage>–<lpage>369</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/scan/nsaa044.</pub-id><pub-id pub-id-type="pmid">32248238</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Carhart-Harris</surname><given-names>RL</given-names></name>
<name><surname>Friston</surname><given-names>KJ</given-names></name>
</person-group> (<year>2019</year>) <article-title>REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics</article-title>. <source>Pharmacol Rev</source>
<volume>71</volume>: <fpage>316</fpage>–<lpage>344</lpage>. DOI: <pub-id pub-id-type="doi">10.1124/pr.118.017160.</pub-id><pub-id pub-id-type="pmid">31221820</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Carhart-Harris</surname><given-names>RL</given-names></name>
<name><surname>Bolstridge</surname><given-names>M</given-names></name>
<name><surname>Day</surname><given-names>CMJ</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up</article-title>. <source>Psychopharmacology</source>
<volume>235</volume>: <fpage>399</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">29119217</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Carhart-Harris</surname><given-names>RL</given-names></name>
<name><surname>Erritzoe</surname><given-names>D</given-names></name>
<name><surname>Williams</surname><given-names>T</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>109</volume>: <fpage>2138</fpage>–<lpage>2143</lpage>. DOI: <pub-id pub-id-type="doi">10.1073/pnas.1119598109.</pub-id><pub-id pub-id-type="pmid">22308440</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Carhart-Harris</surname><given-names>RL</given-names></name>
<name><surname>Kaelen</surname><given-names>M</given-names></name>
<name><surname>Bolstridge</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>The paradoxical psychological effects of lysergic acid diethylamide (LSD)</article-title>. <source>Psychol Med</source>
<volume>46</volume>: <fpage>1379</fpage>–<lpage>1390</lpage>. DOI: <pub-id pub-id-type="doi">10.1017/S0033291715002901.</pub-id><pub-id pub-id-type="pmid">26847689</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Carhart-Harris</surname><given-names>RL</given-names></name>
<name><surname>Roseman</surname><given-names>L</given-names></name>
<name><surname>Bolstridge</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2017</year>) <article-title>Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms</article-title>. <source>Sci Rep</source>
<volume>7</volume>: <publisher-name>13187</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1038/s41598-017-13282-7.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Meng</surname><given-names>X</given-names></name>
<name><surname>Hu</surname><given-names>Q</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Altered resting-state functional organization within the central executive network in obsessive–compulsive disorder</article-title>. <source>Psychiatry Clin Neurosci</source>
<volume>70</volume>: <fpage>448</fpage>–<lpage>456</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/pcn.12419.</pub-id><pub-id pub-id-type="pmid">27377579</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Costa</surname><given-names>PT</given-names></name>
<name><surname>McCrae</surname><given-names>RR</given-names></name>
</person-group> (<year>2008</year>) <article-title>The revised NEO personality inventory (NEO-PI-R)</article-title>. In: <person-group person-group-type="editor">
<name><surname>Boyle</surname><given-names>GJ</given-names></name>
<name><surname>Matthews</surname><given-names>G</given-names></name>
<name><surname>Saklofske</surname><given-names>DH</given-names></name>
</person-group> (eds) <source>The SAGE Handbook of Personality Theory and Assessment: Volume 2 - Personality Measurement and Testing</source>. <publisher-loc>London</publisher-loc>: <publisher-name>SAGE</publisher-name>, pp.<fpage>179</fpage>–<lpage>198</lpage>. DOI: <pub-id pub-id-type="doi">10.4135/9781849200479.n9.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>AK</given-names></name>
<name><surname>Barrett</surname><given-names>FS</given-names></name>
<name><surname>May</surname><given-names>DG</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial</article-title>. <source>JAMA Psychiatry</source>
<volume>78</volume>: <fpage>481</fpage>–<lpage>489</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.3285.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Doss</surname><given-names>MK</given-names></name>
<name><surname>May</surname><given-names>DG</given-names></name>
<name><surname>Johnson</surname><given-names>MW</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>The acute effects of the atypical dissociative hallucinogen salvinorin A on functional connectivity in the human brain</article-title>. <source>Sci Rep</source>
<volume>10</volume>: <publisher-name>16392</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1038/s41598-020-73216-8.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Erritzoe</surname><given-names>D</given-names></name>
<name><surname>Roseman</surname><given-names>L</given-names></name>
<name><surname>Nour</surname><given-names>MM</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Effects of psilocybin therapy on personality structure</article-title>. <source>Acta Psychiatr Scand</source>
<volume>138</volume>: <fpage>368</fpage>–<lpage>378</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/acps.12904.</pub-id><pub-id pub-id-type="pmid">29923178</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ettrup</surname><given-names>A</given-names></name>
<name><surname>da Cunha-Bang</surname><given-names>S</given-names></name>
<name><surname>McMahon</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2014</year>) <article-title>Serotonin 2A receptor agonist binding in the human brain with [11 C]Cimbi-36</article-title>. <source>J Cereb Blood Flow Metab</source>
<volume>34</volume>: <fpage>1188</fpage>–<lpage>1196</lpage>. doi: <pub-id pub-id-type="doi">10.1038/jcbfm.2014.68.</pub-id><pub-id pub-id-type="pmid">24780897</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ettrup</surname><given-names>A</given-names></name>
<name><surname>Svarer</surname><given-names>C</given-names></name>
<name><surname>McMahon</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin</article-title>. <source>NeuroImage</source>
<volume>130</volume>: <fpage>167</fpage>–<lpage>174</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.02.001.</pub-id><pub-id pub-id-type="pmid">26876490</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ferguson</surname><given-names>CJ</given-names></name>
</person-group> (<year>2009</year>) <article-title>An effect size primer: A guide for clinicians and researchers</article-title>. <source>Prof Psychol Res Pr</source>
<volume>40</volume>: <fpage>532</fpage>–<lpage>538</lpage>. DOI: <pub-id pub-id-type="doi">10.1037/a0015808.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Finnema</surname><given-names>SJ</given-names></name>
<name><surname>Stepanov</surname><given-names>V</given-names></name>
<name><surname>Ettrup</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2014</year>) <article-title>Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain</article-title>. <source>NeuroImage</source>
<volume>84</volume>: <fpage>342</fpage>–<lpage>353</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.08.035.</pub-id><pub-id pub-id-type="pmid">23994452</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>PM</given-names></name>
<name><surname>Hariri</surname><given-names>AR</given-names></name>
</person-group> (<year>2012</year>) <article-title>Linking variability in brain chemistry and circuit function through multimodal human neuroimaging</article-title>. <source>Genes Brain Behav</source>
<volume>11</volume>: <fpage>633</fpage>–<lpage>642</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00786.x.</pub-id><pub-id pub-id-type="pmid">22443230</pub-id></mixed-citation>
      </ref>
      <ref id="bibr23-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia-Romeu</surname><given-names>A</given-names></name>
<name><surname>Davis</surname><given-names>AK</given-names></name>
<name><surname>Erowid</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2019</year>) <article-title>Cessation and reduction in alcohol consumption and misuse after psychedelic use</article-title>. <source>J Psychopharmacol</source>
<volume>33</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881119845793.</pub-id><pub-id pub-id-type="pmid">31084460</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gasser</surname><given-names>P</given-names></name>
<name><surname>Holstein</surname><given-names>D</given-names></name>
<name><surname>Michel</surname><given-names>Y</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2014</year>) <article-title>Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases</article-title>. <source>J Nerv Ment Dis</source>
<volume>202</volume>: <fpage>513</fpage>–<lpage>520</lpage>. DOI: <pub-id pub-id-type="doi">10.1097/NMD.0000000000000113.</pub-id><pub-id pub-id-type="pmid">24594678</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>RZ</given-names></name>
<name><surname>Leskovjan</surname><given-names>AC</given-names></name>
<name><surname>Hoff</surname><given-names>AL</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2004</year>) <article-title>Severity of neuropsychological impairment in cocaine and alcohol addiction: Association with metabolism in the prefrontal cortex</article-title>. <source>Neuropsychologia</source>
<volume>42</volume>: <fpage>1447</fpage>–<lpage>1458</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2004.04.002.</pub-id><pub-id pub-id-type="pmid">15246283</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
<name><surname>Johnson</surname><given-names>MW</given-names></name>
<name><surname>Carducci</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial</article-title>. <source>J Psychopharmacol</source>
<volume>30</volume>: <fpage>1181</fpage>–<lpage>1197</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881116675513.</pub-id><pub-id pub-id-type="pmid">27909165</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
<name><surname>Johnson</surname><given-names>MW</given-names></name>
<name><surname>Richards</surname><given-names>WA</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2011</year>) <article-title>Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects</article-title>. <source>Psychopharmacology</source>
<volume>218</volume>: <fpage>649</fpage>–<lpage>665</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-011-2358-5.</pub-id><pub-id pub-id-type="pmid">21674151</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
<name><surname>Richards</surname><given-names>WA</given-names></name>
<name><surname>McCann</surname><given-names>U</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2006</year>) <article-title>Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance</article-title>. <source>Psychopharmacology</source>
<volume>187</volume>: <fpage>268</fpage>–<lpage>283</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-006-0457-5.</pub-id><pub-id pub-id-type="pmid">16826400</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Grob</surname><given-names>CS</given-names></name>
<name><surname>McKenna</surname><given-names>DJ</given-names></name>
<name><surname>Callaway</surname><given-names>JC</given-names></name>
</person-group>, <etal>et al</etal>. (<year>1996</year>) <article-title>Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil</article-title>. <source>J Nerv Ment Dis</source>
<volume>184</volume>: <fpage>86</fpage>–<lpage>94</lpage>. DOI: <pub-id pub-id-type="doi">10.1097/00005053-199602000-00004.</pub-id><pub-id pub-id-type="pmid">8596116</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hasler</surname><given-names>F</given-names></name>
<name><surname>Grimberg</surname><given-names>U</given-names></name>
<name><surname>Benz</surname><given-names>MA</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2004</year>) <article-title>Acute psychological and physiological affects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study</article-title>. <source>Psychopharmacology</source>
<volume>172</volume>: <fpage>145</fpage>–<lpage>156</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-003-1640-6.</pub-id><pub-id pub-id-type="pmid">14615876</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Holm</surname><given-names>S</given-names></name>
</person-group> (<year>1979</year>) <article-title>A simple sequentially rejective multiple test procedure</article-title>. <source>Scand J Stat</source>
<volume>6</volume>: <fpage>65</fpage>–<lpage>70</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr32-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Holst</surname><given-names>KK</given-names></name>
<name><surname>Budtz-Jørgensen</surname><given-names>E</given-names></name>
</person-group> (<year>2013</year>) <article-title>Linear latent variable models: The lava-package</article-title>. <source>Comput Stat</source>
<volume>28</volume>: <fpage>1385</fpage>–<lpage>1452</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00180-012-0344-y.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>WT</given-names></name>
<name><surname>Rosenberg</surname><given-names>MD</given-names></name>
<name><surname>Scheinost</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Resting-state functional connectivity predicts neuroticism and extraversion in novel individuals</article-title>. <source>Soc Cogn Affect Neurosci</source>
<volume>13</volume>: <fpage>224</fpage>–<lpage>232</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/scan/nsy002.</pub-id><pub-id pub-id-type="pmid">29373729</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Innis</surname><given-names>RB</given-names></name>
<name><surname>Cunningham</surname><given-names>VJ</given-names></name>
<name><surname>Delforge</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2007</year>) <article-title>Consensus nomenclature for in vivo imaging of reversibly binding radioligands</article-title>. <source>J Cereb Blood Flow Metab</source>
<volume>27</volume>: <fpage>1533</fpage>–<lpage>1539</lpage>. DOI: <pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600493.</pub-id><pub-id pub-id-type="pmid">17519979</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>CG</given-names></name>
<name><surname>Niclasen</surname><given-names>J</given-names></name>
<name><surname>Vangkilde</surname><given-names>SA</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Research on translations of tests: General inattentiveness is a long-term reliable trait independently predictive of psychological health: Danish validation studies of the mindful attention awareness scale</article-title>. <source>Psychol Assess</source>
<volume>28</volume>: <publisher-name>e70–e87</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1037/pas0000196.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr36-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>MW</given-names></name>
<name><surname>Garcia-Romeu</surname><given-names>A</given-names></name>
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
</person-group> (<year>2017</year>) <article-title>Long-term follow-up of psilocybin-facilitated smoking cessation</article-title>. <source>Am J Drug Alcohol Abuse</source>
<volume>43</volume>: <fpage>55</fpage>–<lpage>60</lpage>. DOI: <pub-id pub-id-type="doi">10.3109/00952990.2016.1170135.</pub-id><pub-id pub-id-type="pmid">27441452</pub-id></mixed-citation>
      </ref>
      <ref id="bibr37-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>MW</given-names></name>
<name><surname>Richards</surname><given-names>WA</given-names></name>
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
</person-group> (<year>2008</year>) <article-title>Human hallucinogen research: Guidelines for safety</article-title>. <source>J Psychopharmacol</source>
<volume>22</volume>: <fpage>603</fpage>–<lpage>620</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881108093587.</pub-id><pub-id pub-id-type="pmid">18593734</pub-id></mixed-citation>
      </ref>
      <ref id="bibr38-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaiser</surname><given-names>RH</given-names></name>
<name><surname>Andrews-Hanna</surname><given-names>JR</given-names></name>
<name><surname>Wager</surname><given-names>TD</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2015</year>) <article-title>Large-scale network dysfunction in major depressive disorder: A meta-analysis of resting-state functional connectivity</article-title>. <source>JAMA Psychiatry</source>
<volume>72</volume>: <fpage>603</fpage>–<lpage>611</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.0071.</pub-id><pub-id pub-id-type="pmid">25785575</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lebedev</surname><given-names>AV</given-names></name>
<name><surname>Lövdén</surname><given-names>M</given-names></name>
<name><surname>Rosenthal</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2015</year>) <article-title>Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin</article-title>. <source>Hum Brain Mapp</source>
<volume>36</volume>: <fpage>137</fpage>–<lpage>153</lpage>. DOI: <pub-id pub-id-type="doi">10.1002/hbm.22833.</pub-id><pub-id pub-id-type="pmid">25270984</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>MH</given-names></name>
<name><surname>Smyser</surname><given-names>CD</given-names></name>
<name><surname>Shimony</surname><given-names>JS</given-names></name>
</person-group> (<year>2013</year>) <article-title>Resting-state fMRI: A review of methods and clinical applications</article-title>. <source>Am J Neuroradiol</source>
<volume>34</volume>: <fpage>1866</fpage>–<lpage>1872</lpage>. DOI: <pub-id pub-id-type="doi">10.3174/ajnr.A3263.</pub-id><pub-id pub-id-type="pmid">22936095</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Z</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Functional connectivity within the executive control network mediates the effects of long-term Tai Chi exercise on elders’ emotion regulation</article-title>. <source>Front Aging Neurosci</source>
<volume>10</volume>: <publisher-name>315</publisher-name>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2018.00315.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr42-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>MacLean</surname><given-names>KA</given-names></name>
<name><surname>Johnson</surname><given-names>MW</given-names></name>
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
</person-group> (<year>2011</year>) <article-title>Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness</article-title>. <source>J Psychopharmacol</source>
<volume>25</volume>: <fpage>1453</fpage>–<lpage>1461</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881111420188.</pub-id><pub-id pub-id-type="pmid">21956378</pub-id></mixed-citation>
      </ref>
      <ref id="bibr43-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Madsen</surname><given-names>MK</given-names></name>
<name><surname>Fisher</surname><given-names>PM</given-names></name>
<name><surname>Burmester</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2019</year>) <article-title>Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels</article-title>. <source>Neuropsychopharmacology</source>
<volume>44</volume>: <fpage>1328</fpage>–<lpage>1334</lpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41386-019-0324-9.</pub-id><pub-id pub-id-type="pmid">30685771</pub-id></mixed-citation>
      </ref>
      <ref id="bibr44-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Madsen</surname><given-names>MK</given-names></name>
<name><surname>Fisher</surname><given-names>PM</given-names></name>
<name><surname>Stenbæk</surname><given-names>DS</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding</article-title>. <source>Eur Neuropsychopharmacol</source>
<volume>33</volume>: <fpage>71</fpage>–<lpage>80</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.euroneuro.2020.02.001.</pub-id><pub-id pub-id-type="pmid">32146028</pub-id></mixed-citation>
      </ref>
      <ref id="bibr45-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Majić</surname><given-names>T</given-names></name>
<name><surname>Schmidt</surname><given-names>TT</given-names></name>
<name><surname>Gallinat</surname><given-names>J</given-names></name>
</person-group> (<year>2015</year>) <article-title>Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?</article-title>
<source>J Psychopharmacol</source>
<volume>29</volume>: <fpage>241</fpage>–<lpage>253</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881114568040.</pub-id><pub-id pub-id-type="pmid">25670401</pub-id></mixed-citation>
      </ref>
      <ref id="bibr46-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mason</surname><given-names>NL</given-names></name>
<name><surname>Kuypers</surname><given-names>KPC</given-names></name>
<name><surname>Müller</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin</article-title>. <source>Neuropsychopharmacology</source>
<volume>45</volume>: <fpage>2003</fpage>–<lpage>2011</lpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41386-020-0718-8.</pub-id><pub-id pub-id-type="pmid">32446245</pub-id></mixed-citation>
      </ref>
      <ref id="bibr47-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Moreno</surname><given-names>FA</given-names></name>
<name><surname>Wiegand</surname><given-names>CB</given-names></name>
<name><surname>Keolani Taitano</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2006</year>) <article-title>Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder</article-title>. <source>J Clin Psychiatry</source>
<volume>67</volume>: <fpage>1735</fpage>–<lpage>1740</lpage>. DOI: <pub-id pub-id-type="doi">10.4088/JCP.v67n1110.</pub-id><pub-id pub-id-type="pmid">17196053</pub-id></mixed-citation>
      </ref>
      <ref id="bibr48-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Müller</surname><given-names>F</given-names></name>
<name><surname>Holze</surname><given-names>F</given-names></name>
<name><surname>Dolder</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens</article-title>. <source>Neuropsychopharmacology</source>
<volume>46</volume>: <fpage>545</fpage>–<lpage>553</lpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41386-020-00906-2.</pub-id><pub-id pub-id-type="pmid">33219313</pub-id></mixed-citation>
      </ref>
      <ref id="bibr49-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy-Beiner</surname><given-names>A</given-names></name>
<name><surname>Soar</surname><given-names>K</given-names></name>
</person-group> (<year>2020</year>) <article-title>Ayahuasca’s “afterglow”: Improved mindfulness and cognitive flexibility in ayahuasca drinkers</article-title>. <source>Psychopharmacology</source>
<volume>237</volume>: <fpage>1161</fpage>–<lpage>1169</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-019-05445-3.</pub-id><pub-id pub-id-type="pmid">31927605</pub-id></mixed-citation>
      </ref>
      <ref id="bibr50-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nichols</surname><given-names>DE</given-names></name>
</person-group> (<year>2016</year>) <article-title>Psychedelics</article-title>. <source>Pharmacol Rev</source>
<volume>68</volume>: <fpage>264</fpage>–<lpage>355</lpage>. DOI: <pub-id pub-id-type="doi">10.1124/pr.115.011478.</pub-id><pub-id pub-id-type="pmid">26841800</pub-id></mixed-citation>
      </ref>
      <ref id="bibr51-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Nielson</surname><given-names>EM</given-names></name>
<name><surname>May</surname><given-names>DG</given-names></name>
<name><surname>Forcehimes</surname><given-names>AA</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions</article-title>. <source>Front Pharmacol</source>
<volume>9</volume>: <publisher-name>132</publisher-name>. DOI: <pub-id pub-id-type="doi">10.3389/fphar.2018.00132.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr52-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Niendam</surname><given-names>TA</given-names></name>
<name><surname>Laird</surname><given-names>AR</given-names></name>
<name><surname>Ray</surname><given-names>KL</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions</article-title>. <source>Cogn Affect Behav Neurosci</source>
<volume>12</volume>: <fpage>241</fpage>–<lpage>268</lpage>. doi: <pub-id pub-id-type="doi">10.3758/s13415-011-0083-5.</pub-id><pub-id pub-id-type="pmid">22282036</pub-id></mixed-citation>
      </ref>
      <ref id="bibr53-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Noorani</surname><given-names>T</given-names></name>
<name><surname>Garcia-Romeu</surname><given-names>A</given-names></name>
<name><surname>Swift</surname><given-names>TC</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts</article-title>. <source>J Psychopharmacol</source>
<volume>32</volume>: <fpage>756</fpage>–<lpage>769</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881118780612.</pub-id><pub-id pub-id-type="pmid">29938565</pub-id></mixed-citation>
      </ref>
      <ref id="bibr54-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Nour</surname><given-names>MM</given-names></name>
<name><surname>Evans</surname><given-names>L</given-names></name>
<name><surname>Nutt</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI)</article-title>. <source>Front Hum Neurosci</source>
<volume>10</volume>: <publisher-name>269</publisher-name>. DOI: <pub-id pub-id-type="doi">10.3389/fnhum.2016.00269.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr55-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pahnke</surname><given-names>WN</given-names></name>
</person-group> (<year>1969</year>) <article-title>The psychedelic mystical experience in the human encounter with death</article-title>. <source>Harv Theol Rev</source>
<volume>62</volume>: <fpage>1</fpage>–<lpage>21</lpage>. DOI: <pub-id pub-id-type="doi">10.1017/S0017816000027577.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr56-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pasquini</surname><given-names>L</given-names></name>
<name><surname>Palhano-Fontes</surname><given-names>F</given-names></name>
<name><surname>Araujo</surname><given-names>DB</given-names></name>
</person-group> (<year>2020</year>) <article-title>Subacute effects of the psychedelic ayahuasca on the salience and default mode networks</article-title>. <source>J Psychopharmacol</source>
<volume>34</volume>: <fpage>623</fpage>–<lpage>635</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881120909409.</pub-id><pub-id pub-id-type="pmid">32255395</pub-id></mixed-citation>
      </ref>
      <ref id="bibr57-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Penny</surname><given-names>W</given-names></name>
<name><surname>Friston</surname><given-names>K</given-names></name>
<name><surname>Ashburner</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2007</year>) <source>Statistical Parametric Mapping: The Analysis of Functional Brain Images, Statistical Parametric Mapping: The Analysis of Functional Brain Images</source>. <publisher-name>Academic Press</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1016/B978-0-12-372560-8.X5000-1.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr58-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Preller</surname><given-names>KH</given-names></name>
<name><surname>Vollenweider</surname><given-names>FX</given-names></name>
</person-group> (<year>2018</year>) <article-title>Phenomenology, structure, and dynamic of psychedelic states</article-title>. <source>Curr Top Behav Neurosci</source>
<volume>36</volume>: <fpage>221</fpage>–<lpage>256</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/7854_2016_459.</pub-id><pub-id pub-id-type="pmid">28025814</pub-id></mixed-citation>
      </ref>
      <ref id="bibr59-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Preller</surname><given-names>KH</given-names></name>
<name><surname>Duerler</surname><given-names>P</given-names></name>
<name><surname>Burt</surname><given-names>JB</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Psilocybin induces time-dependent changes in global functional connectivity</article-title>. <source>Biol Psychiatry</source>
<volume>88</volume>: <fpage>197</fpage>–<lpage>207</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.biopsych.2019.12.027.</pub-id><pub-id pub-id-type="pmid">32111343</pub-id></mixed-citation>
      </ref>
      <ref id="bibr60-02698811211026454">
        <mixed-citation publication-type="webpage">
<collab>R Studio Team</collab> (<year>2020</year>) <article-title>R Studio</article-title>. Available at: <ext-link xlink:href="http://www.rstudio.com/" ext-link-type="uri">http://www.rstudio.com/</ext-link></mixed-citation>
      </ref>
      <ref id="bibr61-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Raichle</surname><given-names>ME</given-names></name>
</person-group> (<year>2011</year>) <article-title>The restless brain</article-title>. <source>Brain Connect</source>
<volume>1</volume>: <fpage>3</fpage>–<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1089/brain.2011.0019.</pub-id><pub-id pub-id-type="pmid">22432951</pub-id></mixed-citation>
      </ref>
      <ref id="bibr62-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Raichle</surname><given-names>ME</given-names></name>
</person-group> (<year>2015</year>) <article-title>The restless brain: How intrinsic activity organizes brain function. Philos</article-title>
<source>Trans R Soc Lond B Biol Sci</source>
<volume>370</volume>: <publisher-name>20140172</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1098/rstb.2014.0172.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr63-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Roseman</surname><given-names>L</given-names></name>
<name><surname>Leech</surname><given-names>R</given-names></name>
<name><surname>Feilding</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2014</year>) <article-title>The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers</article-title>. <source>Front Hum Neurosci</source>
<volume>8</volume>: <publisher-name>204</publisher-name>. DOI: <pub-id pub-id-type="doi">10.3389/fnhum.2014.00204.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr64-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sampedro</surname><given-names>F</given-names></name>
<name><surname>de la Fuente Revenga</surname><given-names>M</given-names></name>
<name><surname>Valle</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2017</year>) <article-title>Assessing the psychedelic “after-glow” in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities</article-title>. <source>Int J Neuropsychopharmacol</source>
<volume>20</volume>: <fpage>698</fpage>–<lpage>711</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/ijnp/pyx036.</pub-id><pub-id pub-id-type="pmid">28525587</pub-id></mixed-citation>
      </ref>
      <ref id="bibr65-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Schaefer</surname><given-names>A</given-names></name>
<name><surname>Kong</surname><given-names>R</given-names></name>
<name><surname>Gordon</surname><given-names>EM</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI</article-title>. <source>Cereb Cortex</source>
<volume>28</volume>: <fpage>3095</fpage>–<lpage>3114</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/cercor/bhx179.</pub-id><pub-id pub-id-type="pmid">28981612</pub-id></mixed-citation>
      </ref>
      <ref id="bibr66-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sheehan</surname><given-names>DV</given-names></name>
<name><surname>Lecrubier</surname><given-names>Y</given-names></name>
<name><surname>Sheehan</surname><given-names>KH</given-names></name>
</person-group>, <etal>et al</etal>. (<year>1998</year>) <article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title>. <source>J Clin Psychiatry</source>
<volume>59</volume>: <fpage>22</fpage>–<lpage>33</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr67-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname><given-names>K</given-names></name>
<name><surname>Welton</surname><given-names>T</given-names></name>
<name><surname>Lyon</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Structural core of the executive control network: A high angular resolution diffusion MRI study</article-title>. <source>Hum Brain Mapp</source>
<volume>41</volume>: <fpage>1226</fpage>–<lpage>1236</lpage>. DOI: <pub-id pub-id-type="doi">10.1002/hbm.24870.</pub-id><pub-id pub-id-type="pmid">31765057</pub-id></mixed-citation>
      </ref>
      <ref id="bibr68-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname><given-names>T</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2015</year>) <article-title>Increased cognition connectivity network in major depression disorder: A fMRI study</article-title>. <source>Psychiatry Investig</source>
<volume>12</volume>: <fpage>227</fpage>–<lpage>234</lpage>. DOI: <pub-id pub-id-type="doi">10.4306/pi.2015.12.2.227.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr69-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname><given-names>X</given-names></name>
<name><surname>Tokoglu</surname><given-names>F</given-names></name>
<name><surname>Papademetris</surname><given-names>X</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2013</year>) <article-title>Groupwise whole-brain parcellation from resting-state fMRI data for network node identification</article-title>. <source>NeuroImage</source>
<volume>82</volume>: <fpage>403</fpage>–<lpage>415</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.05.081.</pub-id><pub-id pub-id-type="pmid">23747961</pub-id></mixed-citation>
      </ref>
      <ref id="bibr70-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Skovdahl-Hansen</surname><given-names>H</given-names></name>
<name><surname>Mortensen</surname><given-names>EL</given-names></name>
<name><surname>Scioetz</surname><given-names>H</given-names></name>
</person-group> (<year>2004</year>) <article-title>Dokumentation for den danske udgave af NEO PI-R og NEO PI-R Kort Version</article-title>. Copenhagen, Denmark: Dansk <source>Psykologisk Forlag</source>.</mixed-citation>
      </ref>
      <ref id="bibr71-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sloshower</surname><given-names>J</given-names></name>
<name><surname>Guss</surname><given-names>J</given-names></name>
<name><surname>Krause</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame</article-title>. <source>J Contextual Behav Sci</source>
<volume>15</volume>: <fpage>12</fpage>–<lpage>19</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jcbs.2019.11.002.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr72-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Smigielski</surname><given-names>L</given-names></name>
<name><surname>Scheidegger</surname><given-names>M</given-names></name>
<name><surname>Kometer</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2019</year>) <article-title>Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects</article-title>. <source>NeuroImage</source>
<volume>196</volume>: <fpage>207</fpage>–<lpage>215</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.04.009.</pub-id><pub-id pub-id-type="pmid">30965131</pub-id></mixed-citation>
      </ref>
      <ref id="bibr73-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Snyder</surname><given-names>HR</given-names></name>
</person-group> (<year>2013</year>) <article-title>Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review</article-title>. <source>Psychol Bull</source>
<volume>139</volume>: <fpage>81</fpage>–<lpage>132</lpage>. DOI: <pub-id pub-id-type="doi">10.1037/a0028727.</pub-id><pub-id pub-id-type="pmid">22642228</pub-id></mixed-citation>
      </ref>
      <ref id="bibr74-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Spies</surname><given-names>M</given-names></name>
<name><surname>Nasser</surname><given-names>A</given-names></name>
<name><surname>Ozenne</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels</article-title>. <source>Hum Brain Mapp</source>
<volume>41</volume>: <fpage>4518</fpage>–<lpage>4528</lpage>. DOI: <pub-id pub-id-type="doi">10.1002/hbm.25138.</pub-id><pub-id pub-id-type="pmid">32697408</pub-id></mixed-citation>
      </ref>
      <ref id="bibr75-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Stenbæk</surname><given-names>DS</given-names></name>
<name><surname>Madsen</surname><given-names>MK</given-names></name>
<name><surname>Ozenne</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans</article-title>. <source>J Psychopharmacol</source>
<volume>35</volume>: <fpage>459</fpage>–<lpage>468</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881120959609.</pub-id><pub-id pub-id-type="pmid">33501857</pub-id></mixed-citation>
      </ref>
      <ref id="bibr76-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Straathof</surname><given-names>M</given-names></name>
<name><surname>Rt Sinke</surname><given-names>M</given-names></name>
<name><surname>Dijkhuizen</surname><given-names>RM</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2019</year>) <article-title>A systematic review on the quantitative relationship between structural and functional network connectivity strength in mammalian brains</article-title>. <source>J Cereb Blood Flow Metab</source>
<volume>39</volume>: <fpage>189</fpage>–<lpage>209</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0271678X18809547.</pub-id><pub-id pub-id-type="pmid">30375267</pub-id></mixed-citation>
      </ref>
      <ref id="bibr77-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Studerus</surname><given-names>E</given-names></name>
<name><surname>Gamma</surname><given-names>A</given-names></name>
<name><surname>Vollenweider</surname><given-names>FX</given-names></name>
</person-group> (<year>2010</year>) <article-title>Psychometric evaluation of the altered states of consciousness rating scale (OAV)</article-title>. <source>PLoS One</source>
<volume>5</volume>: <publisher-name>e12412</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1371/journal.pone.0012412.</pub-id></mixed-citation>
      </ref>
      <ref id="bibr78-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sutherland</surname><given-names>MT</given-names></name>
<name><surname>McHugh</surname><given-names>MJ</given-names></name>
<name><surname>Pariyadath</surname><given-names>V</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>Resting state functional connectivity in addiction: Lessons learned and a road ahead</article-title>. <source>NeuroImage</source>
<volume>62</volume>: <fpage>2281</fpage>–<lpage>2295</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.117.</pub-id><pub-id pub-id-type="pmid">22326834</pub-id></mixed-citation>
      </ref>
      <ref id="bibr79-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Svarer</surname><given-names>C</given-names></name>
<name><surname>Madsen</surname><given-names>K</given-names></name>
<name><surname>Hasselbalch</surname><given-names>SG</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2005</year>) <article-title>MR-based automatic delineation of volumes of interest in human brain PET images using probability maps</article-title>. <source>NeuroImage</source>
<volume>24</volume>: <fpage>969</fpage>–<lpage>979</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2004.10.017.</pub-id><pub-id pub-id-type="pmid">15670674</pub-id></mixed-citation>
      </ref>
      <ref id="bibr80-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tagliazucchi</surname><given-names>E</given-names></name>
<name><surname>Roseman</surname><given-names>L</given-names></name>
<name><surname>Kaelen</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Increased global functional connectivity correlates with LSD-induced ego dissolution</article-title>. <source>Curr Biol</source>
<volume>26</volume>: <fpage>1043</fpage>–<lpage>1050</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.cub.2016.02.010.</pub-id><pub-id pub-id-type="pmid">27085214</pub-id></mixed-citation>
      </ref>
      <ref id="bibr81-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vollenweider</surname><given-names>FX</given-names></name>
<name><surname>Vollenweider-Scherpenhuyzen</surname><given-names>MF</given-names></name>
<name><surname>Bäbler</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. (<year>1998</year>) <article-title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</article-title>. <source>NeuroReport</source>
<volume>9</volume>: <fpage>3897</fpage>–<lpage>3902</lpage>. DOI: <pub-id pub-id-type="doi">10.1097/00001756-199812010-00024.</pub-id><pub-id pub-id-type="pmid">9875725</pub-id></mixed-citation>
      </ref>
      <ref id="bibr82-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Whitfield-Gabrieli</surname><given-names>S</given-names></name>
<name><surname>Ford</surname><given-names>JM</given-names></name>
</person-group> (<year>2012</year>) <article-title>Default mode network activity and connectivity in psychopathology</article-title>. <source>Annu Rev Clin Psychol</source>
<volume>8</volume>: <fpage>49</fpage>–<lpage>76</lpage>. DOI: <pub-id pub-id-type="doi">10.1146/annurev-clinpsy-032511-143049.</pub-id><pub-id pub-id-type="pmid">22224834</pub-id></mixed-citation>
      </ref>
      <ref id="bibr83-02698811211026454">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Whitfield-Gabrieli</surname><given-names>S</given-names></name>
<name><surname>Nieto-Castanon</surname><given-names>A</given-names></name>
</person-group> (<year>2012</year>) <article-title>Conn: A functional connectivity toolbox for correlated and anticorrelated brain networks</article-title>. <source>Brain Connect</source>
<volume>2</volume>: <fpage>125</fpage>–<lpage>141</lpage>. DOI: <pub-id pub-id-type="doi">10.1089/brain.2012.0073.</pub-id><pub-id pub-id-type="pmid">22642651</pub-id></mixed-citation>
      </ref>
      <ref id="bibr84-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Wickham</surname><given-names>H</given-names></name>
</person-group> (<year>2016</year>) <source>ggplot2: Elegant Graphics for Data Analysis</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>. <comment>Available at: <ext-link xlink:href="https://ggplot2.tidyverse.org/" ext-link-type="uri">https://ggplot2.tidyverse.org/</ext-link></comment></mixed-citation>
      </ref>
      <ref id="bibr85-02698811211026454">
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Zeifman</surname><given-names>RJ</given-names></name>
<name><surname>Wagner</surname><given-names>AC</given-names></name>
<name><surname>Watts</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation</article-title>. <source>Front Psychiatry</source>
<volume>11</volume>: <publisher-name>782</publisher-name>. DOI: <pub-id pub-id-type="doi">10.3389/fpsyt.2020.00782.</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
